Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO)
12.55 x 1 35.53 x 1
Pre-market by (Cboe BZX)
31.20 -0.79 (-2.47%) 03/18/25 [NASDAQ]
12.55 x 1 35.53 x 1
Pre-market 31.20 unch (unch) 16:00 ET
Quote Overview for Tue, Mar 18th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
30.81
Day High
31.92
Open 31.61
Previous Close 31.99 31.99
Volume 640,100 640,100
Avg Vol 693,710 693,710
Stochastic %K 12.08% 12.08%
Weighted Alpha -4.11 -4.11
5-Day Change -0.93 (-2.89%) -0.93 (-2.89%)
52-Week Range 27.14 - 62.58 27.14 - 62.58
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,787,635
  • Shares Outstanding, K 57,296
  • Annual Sales, $ 36,500 K
  • Annual Income, $ 673,730 K
  • EBIT $ -426 M
  • EBITDA $ -435 M
  • 60-Month Beta 0.90
  • Price/Sales 50.22
  • Price/Cash Flow N/A
  • Price/Book 1.14

Options Overview Details

View History
  • Implied Volatility 67.79% ( +7.89%)
  • Historical Volatility 38.07%
  • IV Percentile 96%
  • IV Rank 78.73%
  • IV High 80.83% on 05/31/24
  • IV Low 19.51% on 05/16/24
  • Put/Call Vol Ratio 0.03
  • Today's Volume 77
  • Volume Avg (30-Day) 140
  • Put/Call OI Ratio 1.15
  • Today's Open Interest 10,143
  • Open Int (30-Day) 9,732

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.79
  • Number of Estimates 5
  • High Estimate -1.53
  • Low Estimate -2.01
  • Prior Year -1.45
  • Growth Rate Est. (year over year) -23.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.64 +1.83%
on 03/17/25
Period Open: 33.61
36.17 -13.74%
on 02/24/25
-2.41 (-7.17%)
since 02/18/25
3-Month
30.64 +1.83%
on 03/17/25
Period Open: 39.02
39.88 -21.77%
on 12/19/24
-7.82 (-20.04%)
since 12/18/24
52-Week
27.14 +14.96%
on 04/08/24
Period Open: 29.29
62.58 -50.14%
on 11/11/24
+1.91 (+6.52%)
since 03/18/24

Most Recent Stories

More News
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

AGIO : 31.20 (-2.47%)
Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences

The %Biotechnology sector continues to attract investor interest as companies push forward with innovative treatments and breakthrough therapies. Two emerging biotech firms, %CelldexTherapeutics  (NASDAQ:...

AGIO : 31.20 (-2.47%)
CLDX : 19.89 (-2.26%)
Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences

The %Biotechnology sector continues to attract investor interest as companies push forward with innovative treatments and breakthrough therapies. Two emerging biotech firms, %CelldexTherapeutics  (NASDAQ:...

AGIO : 31.20 (-2.47%)
CLDX : 19.89 (-2.26%)
Agios to Present at Upcoming Investor Conferences

AGIO : 31.20 (-2.47%)
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

AGIO : 31.20 (-2.47%)
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues

Agios Pharmaceuticals AGIO incurred a loss of $1.74 per share in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.73. In the year-ago quarter, the company had reported...

AGIO : 31.20 (-2.47%)
HRMY : 34.78 (+1.34%)
PCRX : 23.67 (+1.54%)
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

AGIO : 31.20 (-2.47%)
Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

AGIO : 31.20 (-2.47%)
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

AGIO : 31.20 (-2.47%)
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

AGIO : 31.20 (-2.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.

See More

Key Turning Points

3rd Resistance Point 32.92
2nd Resistance Point 32.42
1st Resistance Point 31.81
Last Price 31.20
1st Support Level 30.70
2nd Support Level 30.20
3rd Support Level 29.59

See More

52-Week High 62.58
Fibonacci 61.8% 49.04
Fibonacci 50% 44.86
Fibonacci 38.2% 40.68
Last Price 31.20
52-Week Low 27.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals